

Testing process

Rhythm Biosciences works with **4Cyte Pathology** to collect and send patient samples to our NATA-accredited facility.

A list of collection facilities is available at colostat.com or scan the QR code here.

We return patient results directly to the referrer, allowing you to act quickly on them.



About Rhythm Biosciences and ColoSTAT®

Rhythm Biosciences is an Australian diagnostics company focused on developing simple, affordable and accurate tests for the early detection of cancers.

Rhythm Biosciences developed ColoSTAT® from innovative CSIRO research.

The technology simplifies the testing process for Colorectal Cancer (CRC) and may help to speed up diagnosis and reduce morbidity and mortality rates.

ColoSTAT® has been clinically validated across multiple populations, with data supporting its ability to detect early-stage CRC with high accuracy.

References

1. Internal data, Rhythm Biosciences 2025
2. AIHW, National Bowel Cancer Screening Program monitoring report 2025
3. <https://www.colostat.com>

AU-HCP-COLOSTAT-1-5

COLOSTAT®
Colorectal Cancer Test

Find out more about how ColoSTAT® can support you to quickly, safely and effectively triage patients with symptoms of CRC by emailing support@rhythmbio.com or visiting www.colostat.com/clinicians.

Rhythm Biosciences, Bio21, 30 Flemington Road, Parkville VIC 3010



Triage potential colorectal cancer patients quickly and effectively with ColoSTAT®^{1,3}



COLOSTAT®
Colorectal Cancer Test

ColoSTAT[®] detects the presence of colorectal neoplasia to support colorectal cancer (CRC) diagnosis in symptomatic patients.^{1,3}

Developed from CSIRO research, ColoSTAT[®] detects serum protein biomarkers to determine the likely presence of CRC. ColoSTAT[®] is intended to aid risk stratification and triage of patients with suspected CRC.

Benefits of ColoSTAT[®] 1,3




Blood sample,
rather than
stool-based.



NPV of 99.4% meaning you can be
confident that a negative result indicates
a patient is very unlikely to have CRC.¹

- ✓ 90% sensitivity, comparable to FIT tests.
- ✓ Directly detects biomarkers of CRC.
- ✓ Clinically safe for patients with symptoms of CRC.
- ✓ Supports risk stratification in complex cases (e.g. persistent ambiguous symptoms, FIT reluctant or frail patients).
- ✓ Can be used to prioritise urgent referrals, potentially reducing delays in diagnosis.
- ✓ Provides patients an alternative to FIT.

ColoSTAT[®] performance^{1,3}



ColoSTAT [®] Sensitivity (%) at each Cancer Stage				
I	II	III	IV	Advanced Adenomas
85.0%	95.7%	84.4%	100.0%	58.0%

Internal data, Rhythm Biosciences 2025

Intended use claim³

ColoSTAT[®] is a quantitative multiplex immunoassay that detects protein biomarkers in human serum. It is intended for people with symptoms of colorectal cancer.

A positive result may indicate the presence of colorectal neoplasia and should be followed up with a colonoscopy.

ColoSTAT[®] is not a replacement for diagnostic colonoscopy, or for surveillance colonoscopy in high-risk individuals.

For patients^{1,3}

- ✓ aged 45-84
- ✓ with symptoms of bowel cancer
- ✓ before or after a FIT test

